BusinessAchillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCVBy Nasdaq OMXNov 30, 2016, 11:05 AM UTC
BusinessAkari Therapeutics to Attend Upcoming Investor Conferences In NovemberBy Nasdaq OMXNov 11, 2016, 12:00 PM UTC
BusinessAkari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York CityBy Nasdaq OMXSep 16, 2016, 4:18 PM UTC
